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Elevated urinary N-acetyl-β-D-
glucosaminidase is associated with 
high glycoalbumin-to-hemoglobin 
A1c ratio in type 1 diabetes patients 
with early diabetic kidney disease
Namki Hong1, Minyoung Lee1, Soyoung Park2, Yong-ho Lee  1, Sang-Man Jin2, Jae Hyeon Kim2 
& Byung-Wan Lee1
Urinary N-acetyl-β-D-glucosaminidase (uNAG) predicted the progression of diabetic kidney disease 
(DKD) prior to development of albuminuria in diabetes patients. We sought whether uNAG level 
is associated with glycoalbumin-to-hemoglobin A1c ratio (G/A ratio), a marker of postprandial 
hyperglycemia and glycemic excursion, independent of albuminuria and kidney function. The 
association between uNAG excretion and G/A ratio was assessed in 204 consecutive subjects with type 1 
diabetes (T1D) (mean age 43.9 years; 49.0% men). uNAG excretion level increased along with older age, 
hyperglycemia, and degree of albuminuria, but was not correlated with body mass index or estimated 
glomerular filtration rate (eGFR). Elevated uNAG showed robust association with higher G/A ratio 
(adjusted β = 0.103, P = 0.020) after adjustment for age, sex, body mass index, duration of diabetes, 
uACR, angiotensin blockers use, fasting plasma glucose, and hemoglobin level. uNAG showed better 
discriminatory performance for individuals with high G/A ratio than albuminuria (AUC 0.613 vs. 0.518, 
P = 0.038). Measurement of uNAG improved AUC for high G/A ratio from 0.699 to 0.748 (P = 0.043) 
when added to conventional risk factors (cutoff 5.24 U/g creatinine; sensitivity 62.5% and specificity 
58.0%). In conclusion, Elevated uNAG was found to be associated with high G/A ratio in patients with 
T1D with early stage DKD, independent of age and albuminuria.
The health and economic burden of diabetic kidney disease (DKD) has increased significantly due to its strong 
association with cardiovascular disease and end-stage renal disease1. Given the reduced risk of albuminuria and 
DKD progression by intensive treatment in early stage DKD demonstrated in previous large trials, the early iden-
tification and monitoring of DKD is critical, particularly in type 1 diabetes (T1D)2. In current clinical practice, 
identification of DKD depends on the assessment of kidney function using estimated glomerular filtration rate 
(eGFR) derived from formulas based on serum creatinine values and kidney damage as reflected by albuminuria1. 
However, eGFR and albuminuria have some limitations in estimating the risk of DKD progression in the early 
stages of DKD. eGFR was shown to be less precise in the higher GFR range due to the potential for overestima-
tion, also referred to as hyperfiltration3. Although albuminuria, usually defined as 30 mg/g creatinine or more, is 
often the first clinical indicator of DKD, prior studies revealed that the relationship of albuminuria to end-stage 
renal disease and cardiovascular disease began even at ‘normal’ levels under the 30 mg/g creatinine cutoff as a 
continuum4. Thus, a more sensitive marker that can reflect subclinical kidney damage due to glucose dysregu-
lation is needed to improve the risk stratification and monitoring of DKD in T1D patients in the early stages of 
DKD.
Urinary N-acetyl-β-D-glucosaminidase (uNAG), a marker of renal proximal tubule injury, is known to 
increase with hyperglycemia, even in normoalbuminuric conditions, and to decrease with improved glycemic 
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control in patients with diabetes5,6. In a nested case-control study of T1D patients with early DKD in the Diabetes 
Control and Complications Trial (DCCT), uNAG and submicroalbuminuric albumin excretion rate predicted the 
onset of micro- and macroalbuminuria, independent of each other7. The association between uNAG and DKD 
progression was shown to be independent of hyperglycemia assessed by hemoglobin A1c (A1c) level, indicat-
ing that uNAG excretion might reflect the hyperglycemia-independent component of glycemic dysregulation7. 
Glycoalbumin (GA)-to-A1c ratio (G/A) ratio has been proposed as a sensitive marker reflecting postprandial 
hyperglycemia, glycemic excursion, and decreased beta cell function capacity in patients with diabetes8–14. 
Postprandial hyperglycemia and glycemic excursion has been postulated as a distinctive, crucial pathogenesis of 
micro- and macrovascular complications15. However, it remains unclear whether elevated uNAG level is associ-
ated with high G/A ratio among T1D patients with early stage DKD.
In this study, we aimed to investigate whether uNAG excretion level is positively associated with G/A ratio, 
independent of albuminuria. We further investigated whether the measurement of uNAG might have additive 
discriminatory value for the identification of T1D patients at risk for progression of DKD, in addition to conven-
tional risk factors such as hyperglycemia and albuminuria.
Materials and Methods
Study participants and design. In this retrospective cross-sectional study, the study population consisted 
of consecutive T1D patients who visited the diabetes clinic of a tertiary-level institution (Samsung Medical Center 
and Severance Hospital, Seoul, Korea) between March 2015 and November 2016. T1D was diagnosed based on 
clinical characteristics, positivity for anti-glutamic acid decarboxylase antibody, or a decreased C-peptide level 
below 0.8 ng/mL at the initial visit. Among 246 subjects, individuals without uNAG data (N = 5), without GA 
measurement (N = 12), and those being treated with sodium-glucose co-transporter 2 inhibitors (N = 7) were 
excluded (Supplementary Fig. 1). Early DKD was defined in accordance with KDIGO guidelines as follows:4 
subjects with normal or mildly decreased GFR (G1 or G2; eGFR ≥ 60 mL/min/1.73 m2) and albuminuria equal to 
or less than a moderately increased level (A1 or A2; < 300 mg/g creatinine). Thus, subjects with eGFR < 60 mL/
min/1.73 m2 (N = 13) or severe albuminuria (N = 11; ≥ 300 mg/g creatinine) were further excluded from anal-
ysis. For the remaining 204 subjects, data regarding demographics, body mass index (BMI), comorbidities, and 
medication use were collected at a single time point defined as the first visit during the study period. None of the 
conditions that might alter albumin or hemoglobin metabolism that could affect A1c and GA values including 
malignancy, liver cirrhosis, hematologic diseases, thyroid dysfunction, regular steroid use, or pregnancy were 
found in any of the subjects after an individual-level medical record review. This study was approved by the insti-
tutional review board of Samsung Medical Center and Severance Hospital (IRB No. 4-2015-0828), which waived 
written informed consent due to the retrospective nature of the study.
Assessment of glucometabolic parameters and kidney function. Fasting blood samples were 
obtained to measure the glucometabolic parameters. A1c level was measured by high-performance liquid chro-
matography using Variant II Turbo (Bio-Rad Laboratories; Hercules, CA, USA; % CV of intra-assay variability 
<1.3%). Serum GA level was determined by enzymatic method using an albumin-specific proteinase, ketoamine 
oxidase, and an albumin assay reagent (LUCICA GA-L assay kit, Asahi Kasei Pharma Co, Tokyo, Japan; % CV 
<3%) using the Hitachi 7699 P module autoanalyzer (Hitachi Instruments Service, Tokyo, Japan). The reference 
ranges of A1c and GA were between 4.0% and 6.0% and between 11.0% and 16.0%, respectively. G/A ratio was 
analyzed as a continuous variable and also as a categorical variable using the cutoff value of 2.8 for high G/A ratio9. 
Serum C-peptide level was assessed using an immunoradiometric assay method (Beckman Coulter, Fullerton, 
CA, USA). Serum concentration of fasting glucose and total cholesterol were measured by standard methods. 
Serum creatinine levels were determined with a Hitachi 7600-110 automated chemistry analyzer (Hitachi Co., 
Tokyo, Japan) with CREA (Roche Diagnostics, Indianapolis, IN, USA) standardized to isotope dilution mass 
spectrometry. As recent study showed that the original Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation and Korean version equation had equivalent overall analytic performance, eGFR was calcu-
lated using the original CKD-EPI equation based on serum creatinine level16,17.
Urinary markers for glomerular and tubular damage. Fasting morning urine sample was used to 
measure urinary albumin, NAG, and creatinine excretion. Albuminuria and NAG excretion was standardized to 
urinary creatinine excretion. Urinary albumin level was measured by an immunoturbidimetric method and urine 
creatinine by a kinetic Jaffe method using an AU680 automated chemistry analyzer (Beckman Coulter, CA, USA). 
Albuminuria was analyzed as a continuous variable or a categorized variable according to KDIGO guidelines 
(normal to mildly increased albuminuria [A1], albumin-to-creatinine ratio (ACR) less than 30 mg/g creatinine, 
n = 176; moderate albuminuria [A2], ACR between 30 and 300 mg/g creatinine, n = 28)4. uNAG was measured 
by an enzymatic method (Nittobo Medical, Fukushima, Japan) using a JCA-BM 6010/c automated chemistry 
analyzer (JEOL Ltd, Tokyo, Japan). A high uNAG level was defined using 5.8 U/g creatinine as a dichotomized 
cutoff, based on the upper normal value in a study of the Japanese population (normal range: 1.6 U/g to 5.8 U/g 
creatinine)18.
Statistical analysis. Data are presented as mean ± SD, median (interquartile range [IQR]), or numbers 
(percentages). Baseline characteristics of subjects were compared using student’s t test, Wilcoxon rank-sum test, 
or Pearson’s chi-square test as appropriate. Median uNAG level or mean log-uNAG level among groups com-
bination of G/A ratio and albuminuria were compared using the Kruskal-Wallis test with Dunn’s procedure or 
analysis of covariance (ANCOVA) with adjustment for age and duration of diabetes. Due to the non-normality 
distribution of the uNAG level that exhibited a right-skewed pattern (Kolmogorov-Smirnov P < 0.01), natural 
log-transformed uNAG (log-uNAG, Kolmogorov-Smirnov P = 0.963) was used in the correlation analyses and 
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regression models. The correlation between log-uNAG, glucometabolic parameters, and log-transformed uACR 
(log-uACR) was assessed by Pearson’s correlation coefficient. Multivariate linear regression models were built to 
elucidate the independent association of uNAG with the G/A ratio after adjustment for covariates including age, 
sex, BMI, duration of diabetes, log-uACR, angiotensin blockers use, fasting plasma glucose, and hemoglobin 
level. For sensitivity analysis, uNAG was entered into multivariate linear regression model as either a continuous 
variable (log-uNAG) or a categorical variable (uNAG quintiles). Area under the receiver operating characteristic 
curve (AUC) was compared to evaluate whether uNAG measurement could further improve the identification of 
individuals with high G/A ratio, in addition to conventional risk factors including uACR, with calculation of the 
optimal cutoff using Youden’s index19. We calculated category-free net reclassification improvement (NRI), abso-
lute integrated discrimination improvement (IDI), and relative IDI described by Pencina et al., with the help of 
STATA add-on20. Two-sided P values less than 0.05 were considered statistically significant. All statistical analyses 
were performed using STATA 14.0 (StataCorp, College Station, TX, USA).
Data availability. The datasets used and/or analyzed during this study are available from the corresponding 
author on reasonable request.
Results
Baseline characteristics of the study participants. The mean age of the study participants was 
43.9 ± 14.9 years and 100 (49.0%) were men (Table 1). The median uNAG level was 5.6 U/g creatinine with an 
interquartile range of 3.2–9.9. Compared with subjects with uNAG levels within the predefined normal range 
(N = 105, 51.5%), those with high uNAG levels were older in age and had higher GA, A1c, and ACR levels. The 
High uNAG group had longer diabetes duration and marginally higher fasting plasma glucose levels, whereas 
BMI did not differ significantly between two groups.
Correlation between urinary markers and glucometabolic parameters. Log-uNAG showed a 
modest positive correlation with log-uACR (r = 0.422, P < 0.001; Table 2). As expected, both log-uNAG and 
log-uACR were positively correlated with HbA1c (r = 0.339 and r = 0.252, respectively) and GA (r = 0.321 and 
r = 0.212, respectively), but eGFR (r = −0.166 and r = −0.142, respectively) showed a negatively weak correla-
tion with both urinary markers, with significance. A distinctive pattern was observed between log-uNAG and 
log-uACR in terms of age and diabetes duration: elevated log-uNAG was more closely associated with older age, 
whereas log-uACR was positively correlated with longer duration of diabetes. BMI and systolic blood pressure did 
not show a significant linear correlation with either log-uNAG or log-uACR.
Determinants of uNAG excretion. Independent determinants of log-uNAG level were assessed using 
multivariate regression models in T1D subjects (Table 3). In model 2, higher age, log-uACR, and female sex were 
significantly associated with elevated NAG excretion. When GA or A1c was entered into the model separately 
(models 3 and 4), age was the strongest determinant of log-uNAG level, followed by GA or A1c, independent of 
Total (N = 204)
uNAG ≥ 5.80 U/g 
creatinine N = 99 (48.5%)
uNAG < 5.80 U/g creatinine 
N = 105 (51.5%) P value
Demographics
  Age, year 43.9 ± 14.9 48.9 ± 14.7 39.3 ± 13.6 <0.001
  Male sex 100 (49.0) 42 (42.4) 58 (55.2) 0.067
  Diabetes duration, year 11.7 ± 8.8 13.0 ± 9.8 10.5 ± 7.7 0.049
  BMI, kg/m2 22.9 ± 3.2 23.1 ± 2.9 22.7 ± 3.5 0.422
  SBP, mmHg 121.3 ± 17.4 120.6 ± 17.0 122.0 ± 16.1 0.654
  Hemoglobin, g/dL 13.8 ± 1.7 13.6 ± 1.7 14.0 ± 1.6 0.104
Glucometabolic parameters
  FPG, mg/dL 162.8 ± 69.2 171.5 ± 73.7 154.5 ± 64.0 0.080
  Glycoalbumin, % 23.4 ± 6.5 25.5 ± 7.2 21.4 ± 5.1 < 0.001
  A1c, % (mmol/mol) 7.7 (61) ± 1.4 8.3 (67) ± 1.5 7.2 (55) ± 1.2 < 0.001
  Fasting C-peptide, ng/mL 0.13 [0.02–0.54] 0.09 [0.02–0.48] 0.20 [0.04–0.66] 0.036
  Cholesterol, mg/dL 170.9 ± 32.9 173.0 ± 38.0 168.8 ± 27.3 0.365
DN markers
  eGFR, ml/min/1.73 m2 101.4 ± 18.0 97.7 ± 19.1 104.9 ± 16.2 0.004
  uACR, mg/g 8.8 [5.5–16.2] 13.0 [8.0–26.4] 6.1 [4.1–10.1] <0.001
  uNAG, U/g creatinine 5.6 [3.2–9.9] 10.3 [7.7–16.8] 3.3 [2.2–4.6] <0.001
Table 1. Baseline characteristics of the study subjects by uNAG excretion level. Data are presented as 
mean ± standard deviation, median [interquartile range], or as numbers (%). Bold characters represent 
statistically significant values. Abbreviations: A1c, hemoglobin A1c; BMI, body mass index; SBP, systolic 
blood pressure; FPG, fasting plasma glucose; DN, diabetic nephropathy; uNAG, urinary N-acetyl-β-D-
glucosaminidase to creatinine ratio; eGFR, estimated glomerular filtration rate; uACR, urinary albumin-to-
creatinine ratio.
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log-uACR level. Log-uNAG level did not differ significantly according to BMI, duration of diabetes, or eGFR in 
this study.
Comparison of uNAG level by G/A ratio and albuminuria groups. When subjects were grouped into 
4 groups according to a combination of G/A ratio (low: < 2.8 vs. high: ≥ 2.8) and albuminuria (normoalbuminu-
ria <30 mg/g creatinine vs. microalbuminuria ≥ 30 mg/g creatinine; Fig. 1), subjects with high G/A ratios had 
higher median uNAG excretion levels compared to those with low G/A ratios in both the normoalbuminuria 
(5.5 vs. 4.8 U/g creatinine, P = 0.049) and microalbuminuria groups (8.6 vs. 5.9 U/g creatinine, P = 0.036). When 
mean log-uNAG levels were compared, higher mean log-uNAG level was observed in high G/A ratio group than 
in low G/A ratio group, even after adjustment for age and duration of diabetes (in overall: 1.9 vs 1.5 log-U/g 
creatinine, P = 0.004; in normoalbuminuria group: 1.8 vs 1.5 log-U/g creatinine, P = 0.047; in microalbuminuria 
group: 2.5 vs. 1.4 log-U/g creatinine, P = 0.012).
Association between uNAG and G/A ratio. In T1D subjects with early DKD, elevated log-uNAG 
was associated with higher G/A ratios (Table 4; unadjusted β = 0.092, P = 0.015), whereas log-uACR did not 
show a significant association. The positive association of log-uNAG with the G/A ratio was robust (adjusted 
β = 0.103, P = 0.020) even after adjustment for potential covariates including age, sex, BMI, duration of diabe-
tes, log-uACR, angiotensin blockers use, fasting plasma glucose, and hemoglobin level. When the analysis was 
confined to subjects with normal to mildly increased albuminuria (A1, uACR < 30 mg/g creatinine; n = 176), 
subjects with high uNAG (≥5.8 U/g creatinine) had higher GA (20.9 vs. 24.8%, P < 0.001), higher A1c (8.1 vs. 
7.2, P < 0.001), and higher G/A ratio (3.1 vs. 2.8, P = 0.044) compared to subjects with low uNAG level (<5.8 
U/g creatinine; Supplementary Fig. 2). Positive association of log-uNAG with G/A ratio remained independent 
(adjusted β = 0.127, P = 0.011) in subjects with A1 state (Supplementary Table 1). When uNAG was entered into 
the multivariate model as categorical variable (quintiles) for sensitivity analysis, we observed increasing trend of 
Log-uNAG
P
Log-uACR
Pr r
Age, year 0.319 <0.001 0.109 0.117
BMI, kg/m2 0.011 0.874 −0.033 0.643
Diabetes duration, year 0.087 0.214 0.162 0.019
SBP, mmHg 0.032 0.736 0.149 0.117
Hemoglobin, g/dL −0.096 0.170 −0.078 0.265
FPG, mg/dL 0.079 0.261 0.141 0.043
Glycated albumin, % 0.321 <0.001 0.212 0.002
A1c, % 0.339 <0.001 0.252 0.003
eGFR, mL/min/1.73 m2 −0.166 0.017 −0.142 0.042
uNAG, log unit* — — 0.422 <0.001
uACR, log unit* 0.422 <0.001 — —
Table 2. Correlation between urinary markers and glucometabolic parameters. *uNAG and uACR were log-
transformed to achieve normal distribution for calculating Pearson correlation coefficients. Bold characters 
represent statistically significant values. Abbreviations: A1c, hemoglobin A1c; BMI, body mass index; SBP, 
systolic blood pressure; FPG, fasting plasma glucose; uNAG, urinary N-acetyl-β-D-glucosaminidase; eGFR, 
estimated glomerular filtration rate; uACR, urinary albumin-to-creatinine ratio.
Variables
Model 1 Model 2 Model 3 Model 4
st β* P st β P st β P st β P
Age 0.331 <0.001 0.302 <0.001 0.312 <0.001 0.309 <0.001
Women vs. men 0.191 0.006 0.126 0.050 0.133 0.029 0.141 0.021
Diabetes duration −0.018 0.800 −0.066 0.322 −0.053 0.397 −0.038 0.548
BMI −0.001 0.990 0.013 0.834 0.039 0.511 −0.001 0.975
Log-uACR 0.369 <0.001 0.306 < 0.001 0.288 <0.001
Glycoalbumin 0.282 <0.001
A1c 0.285 < 0.001
Table 3. Determinants of uNAG excretion level in subjects with type 1 diabetes. *Standardized beta coefficient 
was calculated to compare the relative contribution of each variable in determining the uNAG excretion 
level. Covariates included in each model are as follows: Model 1: age, sex, duration of diabetes, BMI; model 2: 
model 1 + log-uACR; model 3: model 2 + glycoalbumin; model 4: model 2 + hemoglobin A1c. Bold characters 
represent statistically significant values. uNAG and uACR were log-transformed for linear regression models. 
Abbreviations: A1c, hemoglobin A1c; uNAG, urinary N-acetyl-β-D-glucosaminidase; BMI, body mass index; 
uACR, urinary albumin-to-creatinine ratio.
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G/A ratio from lowest to higher quintiles of uNAG, where subjects with uNAG at fourth (uNAG 7.17–11.61 U/g) 
and fifth quintiles (uNAG ≥ 11.62 U/g) showed association with elevated G/A ratio in the multivariate model 
(adjusted β = 0.241, P = 0.048 and adjusted β = 0.324, P = 0.014, respectively) compared to those with lowest 
(first) uNAG quintile (uNAG 0.63–2.77 U/g). Subjects with second (2.78–4.70 U/g) and third uNAG quintiles 
(4.80–7.16 U/g) showed increasing G/A ratio in multivariate model (adjusted β = 0.097, P = 0.379 and adjusted 
β = 0.087, P = 0.483, respectively), although it did not reach statistical significance.
Additive discriminatory value of uNAG for subjects with high G/A ratio. The discriminatory value 
of uNAG for high G/A ratio was assessed by comparing the area under the curve (AUC) in a receiver operat-
ing characteristic (ROC) analysis (Fig. 2). The AUC of log-uNAG alone for discrimination of high G/A ratio 
was 0.613, which was significantly higher than the AUC of the log-uACR (0.613 vs. 0.518, P = 0.038). When 
log-uNAG level was added to the conventional risk factors including log-uACR, age, sex, BMI, diabetes duration, 
angiotensin blocker use, fasting plasma glucose, and hemoglobin level, its discriminatory performance signif-
icantly improved from AUC 0.699 to 0.748 (P = 0.043). The optimal cutoff of uNAG for high glycemic varia-
bility (G/A ratio ≥ 2.8) was 5.24 U/g creatinine (1.65 log unit), with a sensitivity and specificity of 62.5% and 
58.0%, respectively. Measurement of log-uNAG significantly improved the identification of high glycemic vari-
ability when added to conventional model including log-uACR (category-free NRI 0.342, 95% CI 0.040–0.643, 
P = 0.027; absolute IDI 0.042, 95% CI 0.016–0.067, P = 0.002; relative IDI 0.357, 95% CI 0.123–0.590, P = 0.002), 
which was consistent with the results of the ROC analysis.
Figure 1. Comparison of uNAG level by combining the glycoalbumin-to-hemoglobin A1c (G/A) ratio and 
presence of albuminuria in subjects with type 1 diabetes. Low G/A ratios are indicated by values less than 2.8, 
whereas G/A ratios equal to 2.8 or more were defined as high. Albuminuria was defined as urinary albumin-
to-creatinine ratio equal to or greater than 30 mg/g creatinine. P values for comparison between groups were 
calculated using Dunn’s procedure in order to correct for multiple comparison error. Abbreviations: uNAG, 
urinary N-acetyl-β-D-glucosaminidase; G/A ratio, glycoalbumin-to-hemoglobin A1c ratio.
Variables
Univariate
P
Multivariate
PUnadjusted β (95% CI) Adjusted β (95% CI)
uNAG, log unit 0.092 (0.018 to 0.166) 0.015 0.103 (0.016 to 0.189) 0.020
Age, year 0.001 (−0.058 to 0.060) 0.971 −0.001 (−0.005 to 0.004) 0.761
Women (vs. men) 0.089 (−0.040 to 0.220) 0.177 0.016 (−0.119 to 0.153) 0.811
BMI, kg/m2 −0.030 (−0.051 to −0.008) 0.005 −0.028 (−0.049 to −0.007) 0.007
Diabetes duration, year 0.105 (−0.024 to 0.234) 0.112 0.173 (0.041 to 0.313) 0.011
uACR, log unit 0.033 (−0.028 to 0.095) 0.286 −0.007 (−0.080 to 0.075) 0.952
Angiotensin blockers use (yes vs. no) −0.121 (−0.300 to 0.058) 0.185 −0.212 (−0.417 to 0.005) 0.055
FPG, mg/dL 0.014 (0.005 to 0.024) 0.002 0.016 (0.006 to 0.025) 0.002
Hemoglobin, g/dL −0.014 (−0.053 to 0.024) 0.471 0.006 (−0.033 to 0.045) 0.782
Table 4. Association of uNAG excretion with G/A ratio in subjects with type 1 diabetes. uNAG and uACR 
were log-transformed for linear regression models (log-uNAG and log-uACR). In multivariate model, β 
coefficient of uNAG for G/A ratio was reported with adjustment for age, sex, BMI, duration of diabetes, log-
uACR, angiotensin blockers use, FPG, and hemoglobin. Bold characters represent statistically significant values. 
Abbreviations: uNAG, urinary N-acetyl-β-D-glucosaminidase; BMI, body mass index; uACR, urinary albumin-
to-creatinine ratio.
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Discussion
In this study, we found that the uNAG level was significantly elevated in subjects with T1D in the early stages of 
DKD with high G/A ratio compared to those with normal to low G/A ratio. The association between elevated 
uNAG and high G/A ratio was independent of the presence of albuminuria. uNAG showed better discriminatory 
performance for individuals with high G/A ratio compared to uACR. Measurement of the uNAG level in T1D 
significantly improved identification of subjects with high G/A ratio in addition to conventional risk factors 
including age, duration of diabetes, and albuminuria.
It is well known that kidney tubule damage plays an important role in the pathogenesis of DKD21. uNAG, a 
130 kDa-sized lysosomal enzyme in the proximal tubule epithelial cells, is a well-studied specific marker of renal 
tubular injury22. Regarding the clinical relevance of uNAG in terms of conventional glucometabolic risk factors, 
uNAG level was known to be higher in patients with diabetes compared to healthy controls and to increase along 
with age, hyperglycemia, and the degree of albuminuria5. Even before the development of albuminuria, uNAG 
excretion was found to be positively correlated with hyperglycemia and diabetes duration5. Among our T1D 
subjects, the median uNAG level (5.6 U/g creatinine) fell within the reported range of values in various popula-
tions with diabetes (2.0–10.1 U/g creatinine), which was close to the range reported in a study of T1D subjects of 
similar age18,23–25. In accordance with previous findings, age was the most important determinant of uNAG level 
with significant linear correlation in this study, followed by poor glycemic control (A1c or GA level) and degree 
of albuminuria (ACR) in the submicroalbuminuric range.
In this study, we found that an elevated uNAG level was associated with high G/A ratio, independent of hyper-
glycemia and albuminuria, in type 1 diabetes patients in the very early stages of DKD with intact kidney func-
tion and normo- (in most cases, 86.3%) to microalbuminuria. A better discriminatory performance of uNAG 
for subjects with high G/A ratio was observed compared to albuminuria in our study subjects. Our finding is 
supported by findings from previous studies in which an elevation of uNAG excretion was reported to precede 
the development of albuminuria, decline of eGFR, and progression to fulminant DKD, even in prediabetes sub-
jects5–7,23. These findings emphasize the potential role of renal tubular injury as a primary pathophysiology in 
early DKD21,26. Although proteinuria derived from glomerular leakage is known to induce tubulointerstitial 
damage, studies using urinary tubule injury markers, including uNAG, support that proximal tubule injury con-
tributes as a priming event to the development of early DKD via hyperplasia, hyperresorption, and tubular senes-
cence leading to glomerular hyperfiltration, interstitial inflammation, and glomerulosclerosis21,26. However, as 
suggested by the results from the DCCT, sustained hyperglycemia at fasting status alone could not fully explain 
the observed association between uNAG and the development of albuminuria7. Postprandial hyperglycemia has 
been noted as an important risk factor for progression of renal arteriosclerosis and tubulointerstitial lesions27. 
Monnier and colleagues reported that glucose fluctuation caused a more specific triggering effect on oxidative 
stress than did chronic sustained hyperglycemia in patients with diabetes28. G/A ratio has been proposed as a 
marker of postprandial hyperglycemia, glycemic excursion, and decreased insulin secretion capacity, which was 
also associated with the presence of DKD8,10–14,29. In line with these findings, we found that a urinary tubular 
damage marker, uNAG, was positively associated with G/A ratio, independent of albuminuria and fasting glu-
cose level. Even when analyses were confined to subjects without albuminuria, small but discernable elevation of 
median uNAG level was observed in high G/A ratio group compared to normal G/A ratio group. The elevation of 
uNAG level was more prominent in albuminuria group, suggesting the distinctive role of uNAG reflecting early 
Figure 2. Measurement of uNAG improved the identification of subjects with higher G/A ratios, in addition 
to conventional risk factors such as uACR. The solid line, very short dash line, dash line, and line with small 
cross represent the discriminatory ability characterized by the area under the curve (AUC) for log-uNAG 
alone, log-uACR alone, for the model that included conventional risk factors (log-uACR, age, sex, BMI, 
diabetes duration, angiotensin blocker use, eGFR, and fasting plasma glucose level), and for the composite of 
log-uNAG and the conventional risk model, respectively. Abbreviations: log-uNAG, log-transformed urinary 
N-acetyl-β-D-glucosaminidase; log-uACR, log-transformed urinary albumin-to-creatinine ratio; ROC, receiver 
operating characteristics curve; BMI, body mass index; eGFR, estimated glomerular filtration rate; G/A ratio, 
glycoalbumin-to-hemoglobin A1c ratio.
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renal tubular damage in T1D patients. Furthermore, uNAG measurement improved the discrimination for sub-
jects with high G/A ratio when added to conventional risk factors. Taken together, our findings may support the 
potential utility of uNAG as a sensitive renal tubular damage marker which reflects poor glycemic control status 
in very early stage of DKD, particularly before the onset of albuminuria, although further prospective studies are 
needed to validate these findings.
We acknowledge that the current study has several limitations. Due to the cross-sectional design of this study, 
we could not make any inference on causality. Although a nested case-control study with relatively small sample 
size provided evidence regarding the association of uNAG and progression of DKD, whether individuals with ele-
vated uNAG actually progress to develop advanced DKD, independent of the albuminuria, should be confirmed 
in long-term, large prospective studies7. Although several studies suggested the potential utility of G/A ratio as a 
indicator of postprandial hyperglycemia, glycemic excursion, decreased beta cell capacity, and presence of DKD, 
whether G/A ratio actually mediates the association between uNAG with progression of DKD or onset of other 
vascular complications of diabetes need to be further investigated8,10–14,29. Blood and urine samples obtained at a 
single time were measured. It would be helpful to consolidate our findings by measuring other markers of renal 
tubule injury, which were not available in this study7. Koki Mise and colleagues provided evidence that interstitial 
fibrosis and tubular atrophy score had superior prognostic utility than uNAG for progression of diabetic nephrop-
athy in patients with type 2 diabetes30. Although renal biopsy data were not available in this study, further study 
with tubulointerstitial pathology might strengthen our hypothesis on the association between glycemic variability 
and early tubulointerstitial change. Angiotensin blockers are known to decrease uNAG excretion31. Although 
information regarding the dosing and duration of angiotensin blockers could not be analyzed, we adjusted the use 
of angiotensin blockers at the time of measurement as a dichotomized variable in the multivariate model, which 
did not attenuate the association between uNAG and G/A ratio.
Conclusions
Elevated uNAG excretion was associated with subjects with high G/A ratio among T1DM patients with early 
DKD, independent of age, BMI, fasting glucose level, and albuminuria. uNAG measurement improved the ability 
to discriminate individuals with high G/A ratio, in addition to conventional risk factors. Our findings might 
suggest the potential role of uNAG as an early tubular damage marker reflecting poor glycemic control in patients 
with type 1 diabetes at early stage of DKD, independent of albuminuria.
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